Independent research organization NHRI launches spin-off 'TaiU', securing $2 million in funding for advancements in vaccine development.
Taiwan Universe BioMedicine (TaiU) Steps Forward in Global Vaccine Market
Taiwan Universe BioMedicine (TaiU), a promising biotech company based in Taiwan, is making strides in the global vaccine market. The company, which recently completed a NT$60 million seed funding round, is working on a bivalent enterovirus vaccine and a seasonal influenza Virus-Like Particle (VLP) vaccine.
The funding round, led by Mosaic Seed Fund, also secured a matching investment from the National Development Fund. The funds will be allocated towards preclinical trials for TaiU's products.
Professor Peter Chang, a former member of the Control Yuan, has endorsed TaiU's link between the 'R&D National Team' and the 'Industry National Team', emphasizing Taiwan's potential to build a world-class biomedical industry ecosystem. He believes that this collaboration will be instrumental in Taiwan's efforts to establish itself as a key player in the global vaccine market.
Discussions with a major international pharmaceutical firm are ongoing regarding the seasonal influenza VLP vaccine. The VLP platform technology of TaiU, which shortens development timelines and represents the future of next-generation vaccines, is gaining international attention for its ability to rapidly respond to mutations.
TaiU's lead product, the bivalent enteroour websiteus vaccine, is in joint venture discussions with Vietnam's largest pharmacy chain, vaccination center chain, and a CDMO. Domestic MOUs with adjuvant biotech companies are creating powerful synergies for TaiU to target the hundred-billion-dollar global vaccine market.
Dr. Mei-shang Ho, Chairperson of the Taiwan Association for Vaccine Industry (TAVI), affirmed the potential of VLP platform technology. She emphasized that it provides a solid foundation for Taiwan to meet the challenges of emerging infectious diseases.
Johnny Yu, TAVI Vice Chairperson and Managing Director at MVL, has emphasized the need for more innovative companies like TaiU with flexible, collaborative business models to fill critical industry gaps in Taiwan. He believes that TaiU, with its innovative approach and strategic collaborations, is well-positioned to make a significant impact in the vaccine industry.
TaiU plans to submit an IND application in 2026 and aims to be listed on the emerging stock market in 2028 as a key member of the "Vaccine Taiwan Team." However, as there are no search results directly addressing the progress or future plans of TaiU in the global vaccine market or specifically about their bivalent enterovirus vaccine and seasonal influenza VLP vaccine, up-to-date details can only be found through TaiU’s official communications, recent press releases, or specialized vaccine industry reports.
The collaboration between Taiwan Universe BioMedicine (TaiU) and various domestic companies, as well as international partners, is indicative of their ambitious stance to penetrate the lucrative global vaccine market, reaching $100 billion in value. The funding gained from the seed round and matching investment will be utilized for preclinical trials (finance, business) of their bivalent enterovirus vaccine and seasonal influenza VLP vaccine (health-and-wellness, medical-conditions).
